Four years after Sanofi shelled out $125 million for global rights to Biond Biologic | The company is handing back the tumor ...
Following positive results from the Phase 1 dose escalation study, BND-22 (SAR444881) is now being tested in Phase 2 trials as monotherapy for patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback